WOLVERINE Study Shows The Benefits of Metastases Directed Therapy

The WOLVERINE study is a major analysis combining patient data from seven phase 2 trials, published in The Lancet Oncology. It looked at 574 men with oligometastatic prostate cancer (meaning up to five spots of cancer spread), mostly to bones or lymph nodes. Six of those trials (472 men) directly compared adding metastasis-directed therapy (MDT) […]

Dr. Sartor Explains the ARTISAN Trial

In a recent presentation, Dr. Oliver Sartor highlighted Lead-212 (Pb-212) as a promising next step in precision radioligand therapy for metastatic castration-resistant prostate cancer. Developed by the same Oslo-based team that introduced Radium-223, Lead-212 is being studied in the ARTISAN (AB001) trial and represents a significant evolution in alpha-emitting radiopharmaceuticals. Its defining features are a […]

One year (almost) of ProstateWarriors.com and where are we?

Trop-2: A Promising Therapeutic Target in Prostate Cancer